Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Andrew Tsai is an analyst at Jefferies. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/02/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | RAPP | Buy Now | Rapport Therapeutics | $25.16 | 39.11% | → $35 | Initiates | → Buy | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | — | — | $10 → $21 | Downgrade | Buy → Hold | Get Alert |
| 02/27/2024 | ANRO | Buy Now | Alto Neuroscience | $11.40 | 189.47% | → $33 | Initiates | → Buy | Get Alert |
| 12/07/2023 | VTGN | Buy Now | Vistagen Therapeutics | $3.48 | 331.03% | $0.2 → $15 | Upgrade | Hold → Buy | Get Alert |
| 03/07/2023 | LXRX | Buy Now | Lexicon Pharmaceuticals | $1.65 | 81.82% | → $3 | Initiates | → Hold | Get Alert |
| 06/23/2022 | ATHA | Buy Now | Athira Pharma | $2.51 | 19.42% | $32 → $3 | Downgrade | Buy → Hold | Get Alert |
| 03/16/2022 | BEKE | Buy Now | KE Holdings | $14.87 | 7.6% | $23 → $16 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/01/2022 | VIGL | Buy Now | Vigil Neuroscience | $3.95 | 406.44% | → $20 | Initiates | → Buy | Get Alert |
